OBJECTIVES: To evaluate the association between improvements in clinical and patient-reported outcomes (PROs) and improvements in workplace and household productivity in axial spondyloarthritis (axSpA) patients treated with certolizumab pegol (CZP), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). METHODS: Analyses used Week (Wk) 24 data from the double-blind, placebo-controlled period of RAPID-axSpA (NCT01087762), for patients originally randomized to CZP. Responders and non-responders for clinical outcomes and PROs were compared in terms of change from baseline (CFB) in workplace and household productivity, assessed with the arthritis-specific Work Productivity Survey (WPS). Groups were compared using a non-parametric bootstrap-t method. LOCF was used for ASDAS and WPS outcomes; NRI for ASAS40 and PRO MCIDs. RESULTS: CONCLUSIONS: Achievement of clinical responses and symptom relief were associated with increased workplace and household productivity in CZP-treated axSpA patients, including AS and nr-axSpA.